Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kwee Yong

Showing results (81-90 of 188) with videos related to

Pageof 19
Sort By:
Journal of Clinical Pathology|May 16, 2018
Novel genomic findings in multiple myeloma identified through routine diagnostic sequencingGeorgina L Ryland, Kate Jones, Melody Chin, et al.
Ejhaem|October 17, 2024
Myeloid neoplasm post cytotoxic treatment in patients with multiple myelomaKe Xu, Eleanor Kaffo, Robert Baker, et al.
The British Journal of Radiology|August 14, 2018
National survey of imaging practice for suspected or confirmed plasma cell malignanciesOlwen Amy Westerland, Guy Pratt, Majid Kazmi, et al.
British Journal of Haematology|July 14, 2016
Multiple myeloma: patient outcomes in real-world practiceKwee Yong, Michel Delforge, Christoph Driessen, et al.
British Journal of Haematology|June 14, 2016
Multiple myeloma: practice patterns across EuropeMarc S Raab, Michele Cavo, Michel Delforge, et al.
Blood Advances|August 7, 2024
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron databaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
Leukemia & Lymphoma|January 13, 2021
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-setMonica Ziff, Gabrielle Lawson, Dunnya De-Silva, et al.
Ejhaem|June 18, 2025
Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR studyDipal Mehta, Robert Cicero, Laura Chiecchio, et al.
BMC Hematology|May 19, 2016
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Samantha Hinsley, Mónica Ballesteros, et al.
British Journal of Haematology|August 17, 2020
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trialCatherine Atkin, Gulnaz Iqbal, Tim Planche, et al.
Pageof 19

Showing results (81-90 of 188) with videos related to

Sort By:
Pageof 19
Journal of Clinical Pathology|May 16, 2018
Novel genomic findings in multiple myeloma identified through routine diagnostic sequencingGeorgina L Ryland, Kate Jones, Melody Chin, et al.
Ejhaem|October 17, 2024
Myeloid neoplasm post cytotoxic treatment in patients with multiple myelomaKe Xu, Eleanor Kaffo, Robert Baker, et al.
The British Journal of Radiology|August 14, 2018
National survey of imaging practice for suspected or confirmed plasma cell malignanciesOlwen Amy Westerland, Guy Pratt, Majid Kazmi, et al.
British Journal of Haematology|July 14, 2016
Multiple myeloma: patient outcomes in real-world practiceKwee Yong, Michel Delforge, Christoph Driessen, et al.
British Journal of Haematology|June 14, 2016
Multiple myeloma: practice patterns across EuropeMarc S Raab, Michele Cavo, Michel Delforge, et al.
Blood Advances|August 7, 2024
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron databaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
Leukemia & Lymphoma|January 13, 2021
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-setMonica Ziff, Gabrielle Lawson, Dunnya De-Silva, et al.
Ejhaem|June 18, 2025
Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR studyDipal Mehta, Robert Cicero, Laura Chiecchio, et al.
BMC Hematology|May 19, 2016
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Samantha Hinsley, Mónica Ballesteros, et al.
British Journal of Haematology|August 17, 2020
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trialCatherine Atkin, Gulnaz Iqbal, Tim Planche, et al.
Pageof 19